New drug combo tested for Tough-to-Treat prostate cancer
NCT ID NCT07389187
Summary
This early-stage study is testing the safety and initial effectiveness of a new oral drug called LC-K76 when given alongside an immunotherapy drug (Tislelizumab) in men with advanced prostate cancer that has spread to the bones and stopped responding to standard hormone therapies. The study will involve 10 participants who will receive the drug combination for 24 weeks. The main goal is to see if the treatment is safe and to look for early signs that it might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MCRPC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Changzheng hospital
Shanghai, Shanghai Municipality, 201109, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.